Hi @Mason14
Thanks for dropping in to HC.
I wouldn't underestimate the technical ability of the market research company. They specialise in bio market research.
As to why there were no questions on FTO, I can think of several reasons:
* this study was mainly about cardioprotection
* it isn't necessary to discuss a drug's MOA in order to estimate potential revenues. Patient numbers and price are enough.
* the oncologist respondents may not be up as to speed on FTO as RAC shareholders are, and we didn't want to embarrass them.
Hi @Mason14 Thanks for dropping in to HC.I wouldn't...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.75 |
Change
-0.040(2.23%) |
Mkt cap ! $297.9M | |||
| Open | High | Low | Value | Volume |
| $1.79 | $1.79 | $1.72 | $146.2K | 83.61K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2901 | $1.73 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.75 | 994 | 1 |
View Market Depth
| Last trade - 16.10pm 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.74 |
Change
-0.040 ( 1.51 %) |
||||
| Open | High | Low | Volume | ||
| $1.76 | $1.77 | $1.72 | 23546 | ||
| Last updated 15.56pm 17/06/2024 ? | |||||
| RAC (ASX) Chart |
